利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.025 秒)

    Targeting MicroRNAs for metabolic disorders
    2.
    发明授权
    Targeting MicroRNAs for metabolic disorders 有权
    靶向微小RNA代谢紊乱

    公开(公告)号：US08592388B2

    公开(公告)日：2013-11-26

    申请号：US13320873

    申请日：2010-05-19

    申请人： Markus Stoffel ,  Mirko Trajkovski

    发明人： Markus Stoffel ,  Mirko Trajkovski

    IPC分类号： C12N15/11 ,  A61K48/00 ,  C07H21/02 ,  C07H21/04

    CPC分类号： C12N15/115 ,  A61K31/7088 ,  A61K45/06 ,  C12N15/113 ,  C12N2310/113 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3515 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2320/35

    摘要： Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.

    摘要翻译： 本文提供了用于治疗代谢紊乱的方法和组合物。 本文还提供了用于降低血糖水平，降低葡萄糖代谢，改善胰岛素抵抗和降低血浆胆固醇水平的方法和组合物。 在某些实施方案中，所述方法包括抑制miR-103的活性。 在某些实施方案中，所述方法包括抑制miR-107的活性。 在某些实施方案中，miR-103和miR-107两者的活性被抑制。 在某些实施方案中，这样的方法包括施用包含靶向微小RNA的寡核苷酸的化合物。

    ICA512 COUPLES INSULIN SECRETION AND GENE EXPRESSION IN BETA-CELLS
    3.
    发明申请
    ICA512 COUPLES INSULIN SECRETION AND GENE EXPRESSION IN BETA-CELLS 审中-公开

    公开(公告)号：US20090131309A1

    公开(公告)日：2009-05-21

    申请号：US11574568

    申请日：2005-09-02

    申请人： Michele Solimena ,  Hassan Mziauf ,  Mirko Trajkovski

    发明人： Michele Solimena ,  Hassan Mziauf ,  Mirko Trajkovski

    IPC分类号： A61K38/16 ,  C12N5/06 ,  C12Q1/02 ,  C40B30/06 ,  C40B30/04 ,  C12Q1/68 ,  C12N15/87

    CPC分类号： A61K38/1709

    摘要： The present invention relates to a method for stimulating expression of peptide hormones in peptide-hormone secreting endocrine cells or neurons comprising the step of promoting in said cells or neurons the presence or activity (aa) of (i) ICA512; or (ii) a derivative thereof having ICA512 function; or (iii) a fragment of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 wherein said C-terminal fragment has the capability of being targeted to the nucleus; or (iv) a derivative of said fragment of (iii) that may be cleaved by μ-calpain giving rise to a derivative of said C-terminal fragment of ICA512 wherein said derivative of said C-terminal fragment has the capability of being targeted to the nucleus; or (v) a fragment or derivative of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 or derivative thereof wherein said C-terminal fragment or derivative thereof has the capability of interacting with a PIAS protein in said cells or neurons; or (vi) a fragment or derivative of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 or derivative thereof wherein said C-terminal fragment or derivative thereof has the capability of enhancing the nuclear levels, or tyrosine phosphorylation, or DNA binding activity of STATs in said cells or neurons; or (vii) a pro-form of any one of (i) to (vi); and (ab) optionally of μ-calpain or a fragment or derivative thereof having μ-calpain function; or (b) of a C-terminal fragment of ICA512 or a derivative thereof which has the capability of being targeted to the nucleus or which has the capability of interacting with a PIAS protein or of enhancing the nuclear levels, or tyrosine phosphorylation, or DNA binding activity of STATs in said cells or neurons. Additionally, the present invention relates to a method of promoting cell proliferation of peptide-hormone secreting endocrine cells or neurons comprising the step of promoting in said cells or neurons the presence or activity (aa) of (i) ICA512; or (ii) a derivative thereof having ICA512 function; or (iii) a fragment of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 wherein said C-terminal fragment has the capability of being targeted to the nucleus; or (iv) a derivative of said fragment of (iii) that may be cleaved by μ-calpain giving rise to a derivative of said C-terminal fragment of ICA512 wherein said derivative of said C-terminal fragment has the capability of being targeted to the nucleus; or (v) a fragment or derivative of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 or derivative thereof wherein said C-terminal fragment or derivative thereof has the capability of interacting with a PIAS protein in said cells or neurons; or (vi) a fragment or derivative of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 or derivative thereof wherein said C-terminal fragment or derivative thereof has the capability of enhancing the nuclear levels, or tyrosine phosphorylation, or DNA binding activity of STATs in said cells or neurons; or (vii) a pro-form of any one of (i) to (vi); and (ab) optionally of μ-caipain or a fragment or derivative thereof having μ-calpain function; or (b) of a C-terminal fragment of ICA512 or a derivative thereof which has the capability of being targeted to the nucleus or which has the capability of interacting with a PIAS protein or of enhancing the nuclear levels, or tyrosine phosphorylation, or DNA binding activity of STATs in said cells or neurons. It is preferred in accordance with the invention that said endocrine cells are β-cells and that said peptide hormone is insulin.